ERBB2 and osteosarcoma: Unfortunately, dinutuximab for recurrent osteosarcoma did not show efficacy in a phase II trial [72], but the development of bispecific antibodies that inhibit HER2 and GD2 is underway, and their efficacy is expected to be evaluated [73].